Insights & news

European Parliament adopts Health Technology Assessment Regulation

  • 08/10/2018
  • Articles

On 3 October 2018, the European Parliament adopted with a large majority the proposed Regulation on Health Technology Assessment (“HTA”) (the “Regulation” - see also our  article of 1 February 2018).

The initiative on HTA cooperation at the European level had generally been well received in January 2018 when the European Commission first issued its proposal. However, several Member States (such as Germany) questioned the Regulation’s compatibility with the subsidiarity principle and objected to the mandatory uptake of the joint HTA reports and to the oversight to be exercised by the European Commission. National and regional HTA agencies also voiced concerns  over the increased workload that would be caused for them and flagged the need for more robust guarantees to avoid publication and reporting bias by health technology developers.

The amended Regulation as adopted by the European Parliament has given rise to a new flurry of criticism. In particular, patients, together with some left-leaning parties, regret that they were not given a concrete role in the decision-making process along with scientific experts, despite a proposed amendment to that effect. Instead, these stakeholders are only given the right to submit written comments. Similarly, healthcare professionals are as yet not included in the HTA process.

For its part, MedTech Europe raised concerns regarding the inclusion of specific medical devices in the scope of the Regulation at a time when that industry is already spending substantial resources on compliance with the new EU Medical Devices Regulations. MedTech Europe also advocates allowing Member States with similar needs to conduct voluntary joint HTA.

The European Parliament accommodated a major wish of a group of Member States by changing the threshold for the Coordination Group’s decisions from a two-thirds to a qualified majority. That Coordination group, composed of representatives from Member States’ HTA authorities and bodies, is the body entrusted with overseeing joint clinical assessments and other joint work under the Regulation. In addition, national and regional HTA agencies would be entitled to carry out their own additional clinical assessments which they consider necessary to complete the HTA or the overall pricing and reimbursement process on condition that these assessments are “justified, necessary and proportionate”, do not duplicate work carried out at Union level and do not unduly delay patient access to those technologies. However, this attempt to placate certain Member States seems at odds with the harmonisation purpose of the Regulation, which industry (e.g. EFPIA) has been quick to point out.

It remains to be seen how the Regulation will fare before the Council. It seems unlikely at this stage that the legislative process will be completed before the European Parliament elections in May 2019.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 12/03/2019
    • Articles

    Belgium – New legislation in the making on cannabis for medical use

    In light of the growing international scientific consensus on the positive medicinal effects of cannabis, Belgian lawmakers have tabled proposed legislation which, if adopted, would make the use of cannabis for medical purposes legal. A Cannabis Office will be created within the Federal Agency for Medicines and Health Products which will be in charge of the legal production of medical cannabis, establishing a monopoly for the Belgian State on the cultivation, trade, import and export of that product. Other EU member states already have followed a similar legislative route (e.g. the Netherlands). Following the establishment of the Cannabis Office, a call for tenders will be issued for the cultivation of a certain amount of cannabis. Licences will be granted to the successful applicants to cultivate cannabis in specified locations. The Cannabis Office will purchase the harvest and export and/or distribute it. The manufacturing process will be subject to stringent standards. For example, the cannabis will need to have a stable concentration of the active substance as well as a stable ratio of the main active ingredients, i.e. cannabidiol (CBD) and the main psychoactive compound tetrahydrocannabinol (THC). The move comes more than three years after the first cannabis-based medicine (Sativex spray) became authorized and reimbursable in Belgium for certain multiple sclerosis (“MS”) patients. If physicians want to prescribe medicinal cannabis to their patients for pain relief, or the treatment of nausea and reduced appetite during chemotherapy, further regulatory changes will be required.

    Read more
    • 08/03/2019
    • Articles

    Belgium - Bill Tackles Medicine Shortages

    A number of members of parliament introduced last week a private members’ bill that has the twin objectives of tackling medicine shortages and combating the trade in falsified medicines (bill 54 3599/001 – the “Bill” – see attached). Medicine Shortages The Bill will modify the Law of 25 March 1964 to (i) allow the concept of “temporary cessation of supply of medicines” to be determined by Royal Decree; (ii) allow the Minister to make recommendations of suitable therapeutical alternatives in case of temporary shortages of specific medicines; (iii) preclude wholesalers (“WS”) with a public-service WS status from supplying ordinary WS; and (iv) impose particular shortage-related obligations on parallel traders which previously only applied to the marketing authorisation holders. The proposed ban on public-service WS to supply ordinary WS (and therefore limit their supplies to, broadly, other public-service WS, pharmacists and hospitals) is designed to ensure the steady supply of medicines to the local market and, conversely, cut down on exports that threaten public health. Under specific conditions, the ban will not apply to medicines earmarked for clinical trials. Falsified Medicines The Bill establishes criminal sanctions for specific violations of Regulation 2016/161 which lays down safety features for the packaging of medicines for human use. The current caretaker government no longer commands a majority in the federal Chamber of Representatives. However, the Bill may be assured of an ad hoc majority in that it has already been given a time slot in the session of the committee for public health scheduled on 12 March 2019.

    Read more
    • 04/03/2019
    • Articles

    Belgian Competition Authority Will Again Focus on Pharmaceuticals in 2019

    On 1 March 2019, the Belgian Competition Authority published its yearly policy note setting out its enforcement priorities for the year (see attachments). As was the case in previous years, the pharmaceutical sector is one of the BCA’s main targets for action. Once more, the BCA indicates that it deliberately emulates the approach of other national competition authorities in focusing on “all links of the value chain, including prices charged by pharmaceutical firms, competition between distributors with public-service obligations, the competitive dynamics and innovation at the pharmacy level”. Given the pending inquiries in the sector, this announcement again does not come as a surprise. It also reflects the general competition scrutiny of the sector in Europe, as was evidenced by the publication in January 2019 of the Competition Pharmaceutical Enforcement Report by the European Commission (see, Van Bael & Bellis Life Sciences Newsflash of 28 January 2019). In other news relevant to the sector, the BCA also confirms its continued attention to public procurement. Apart from the pharmaceutical sector, the BCA will target telecommunications, distribution, service providers and logistics. All in all, this year’s enforcement priorities closely resemble those applying in 2018.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *